RNAC
BEARISH
$7.04
Live
Cartesian Therapeutics, Inc. · NASDAQ
Target $35.57
(+405.3%)
$5.6
52W Range
$15.57
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$186.62M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
RNAC exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in nearly all fundamental health categories. The company suffers from negative equity (Price/Book of -1.45) and an unsustainable operating margin of -2316.68%. While analysts maintain a 'strong_buy' rating with a target of $35.57, this is completely decoupled from the current financial reality of massive earnings misses and negative EPS growth. The combination of insider selling by the CEO and CFO and a 5-year price collapse of 93.8% suggests a high-risk speculative profile.
Key Strengths
Strong short-term liquidity with a Current Ratio of 8.65
High analyst conviction (Strong Buy consensus)
Recent short-term price momentum (1-week gain of 17.7%)
Significant gap between current price and analyst target price
Operating in the high-growth Biotechnology sector
Key Risks
Negative shareholder equity (P/B -1.45)
Extreme valuation relative to sales (P/S 66.72)
Severe operational inefficiency (Operating Margin -2316.68%)
Consistent failure to meet earnings estimates (0/4 beats in last year)
Deeply negative EPS growth (-359.3% YoY)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
9
Weak
5
20
10
10
0
AI Verdict
High-Risk Speculative
Key drivers: Piotroski F-Score 1/9, Negative Book Value, Extreme Operating Losses, Insider Selling
Confidence
90%
Value
5/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 66.72 is exorbitant
- Negative Price/Book ratio
- No Graham Number available due to lack of earnings/assets
Future
20/100
Ref Growth rates
Positives
- High analyst target price
Watchpoints
- YoY EPS growth of -359.3%
- Average earnings surprise of -92.47%
Past
10/100
Ref Historical trends
Positives
No standout positives identified.
Watchpoints
- 5-year price decline of 93.8%
- Consistent quarterly earnings misses
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High Current Ratio (8.65)
Watchpoints
- Piotroski F-Score 1/9
- Negative ROA (-14.82%)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$7.04
Analyst Target
$35.57
Upside/Downside
+405.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RNAC and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
Primary
|
-93.8% | -80.8% | -33.0% | -21.9% | +5.9% | +17.7% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
|
KRRO
Korro Bio, Inc.
Peer
|
-97.3% | -46.2% | -2.2% | -70.5% | +7.8% | -9.4% |
|
KPTI
Karyopharm Therapeutics Inc.
Peer
|
-94.7% | -87.2% | +100.5% | +45.5% | -8.6% | +35.8% |
|
ACB
Aurora Cannabis Inc.
Peer
|
-96.9% | -52.9% | -20.2% | -29.6% | -0.3% | -2.3% |
RNA
Cartesian Therapeutics, Inc.
Primary
5Y
-93.8%
3Y
-80.8%
1Y
-33.0%
6M
-21.9%
1M
+5.9%
1W
+17.7%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
KRR
Korro Bio, Inc.
Peer
5Y
-97.3%
3Y
-46.2%
1Y
-2.2%
6M
-70.5%
1M
+7.8%
1W
-9.4%
KPT
Karyopharm Therapeutics Inc.
Peer
5Y
-94.7%
3Y
-87.2%
1Y
+100.5%
6M
+45.5%
1M
-8.6%
1W
+35.8%
ACB
Aurora Cannabis Inc.
Peer
5Y
-96.9%
3Y
-52.9%
1Y
-20.2%
6M
-29.6%
1M
-0.3%
1W
-2.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.17
PEG Ratio
N/A
P/B Ratio
-1.45
P/S Ratio
66.72
EV/Revenue
26.51
EV/EBITDA
-0.89
Market Cap
$186.62M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-2316.68%
Gross Margin
N/A
ROE
N/A
ROA
-14.82%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
8.65
Strong
Quick Ratio
8.45
Excellent
Cash/Share
$4.72
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-2316.7%
Net Margin
-9775.7%
Total Assets
$0.3B
Liabilities
$0.4B
Equity
$-0.1B
Debt/Equity
-3.35x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
103%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-09
$-2.71
-242.6% surprise
2025-11-06
$-0.73
-16.0% surprise
2025-08-07
$-0.77
-18.8% surprise
Healthcare Sector Comparison
Comparing RNAC against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Current Ratio
8.65
This Stock
vs
4.68
Sector Avg
+85.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RNAC
Cartesian Therapeutics, Inc.
|
BEARISH | $186.62M | - | -% | -% | $7.04 | |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
|
KRRO
Korro Bio, Inc.
|
BEARISH | $182.88M | - | -110.7% | -% | $12.68 | Compare |
|
KPTI
Karyopharm Therapeutics Inc.
|
BEARISH | $180.35M | - | -% | -134.2% | $8.0 | Compare |
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $194.51M | - | -15.5% | -22.5% | $3.43 | Compare |
RNAC
Cartesian...
BEARISH
Mkt Cap
$187M
P/E
-
ROE
-%
Price
$7.04
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | KALAYOGLU MURAT | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 758,001 | - |
| 2026-04-02 | HOGE ELIZABETH | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 758,001 | - |
| 2026-03-13 | SINGER MICHAEL S. | Director | Gift | 6,555 | - |
| 2026-01-06 | BRUNN CARSTEN | Chief Executive Officer | Sale | 23,766 | $162,077 |
| 2026-01-06 | DAVIS BLAINE | Chief Financial Officer | Sale | 10,591 | $72,227 |
| 2026-01-06 | MILJKOVIC MILOS | Officer | Sale | 3,573 | $24,367 |
| 2026-01-02 | BARABE TIMOTHY CRAIG | Director | Stock Award | 2,600 | - |
| 2026-01-02 | ZENNER PATRICK J. | Director | Stock Award | 2,600 | - |
| 2026-01-02 | DESILVA NISHAN M | Director | Stock Award | 2,600 | - |
| 2026-01-02 | SPRINGER TIMOTHY A | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 2,600 | - |
| 2026-01-02 | BRUNN CARSTEN | Chief Executive Officer | Stock Award | 143,200 | - |
| 2026-01-02 | MALIK KEMAL | Director | Stock Award | 2,600 | - |
| 2026-01-02 | DAVIS BLAINE | Chief Financial Officer | Stock Award | 37,000 | - |
| 2026-01-02 | SINGER MICHAEL S. | Director | Stock Award | 2,600 | - |
| 2026-01-02 | KALAYOGLU MURAT | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 2,600 | - |
KALAYOGLU MURAT
Beneficial Owner of more than 10% of a Class of Security
2026-04-02
758,001 shares
HOGE ELIZABETH
Beneficial Owner of more than 10% of a Class of Security
2026-04-02
758,001 shares
SINGER MICHAEL S.
Director
2026-03-13
6,555 shares
BRUNN CARSTEN
Chief Executive Officer
2026-01-06
23,766 shares
·
$162,077
DAVIS BLAINE
Chief Financial Officer
2026-01-06
10,591 shares
·
$72,227
MILJKOVIC MILOS
Officer
2026-01-06
3,573 shares
·
$24,367
BARABE TIMOTHY CRAIG
Director
2026-01-02
2,600 shares
ZENNER PATRICK J.
Director
2026-01-02
2,600 shares
DESILVA NISHAN M
Director
2026-01-02
2,600 shares
SPRINGER TIMOTHY A
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-02
2,600 shares
BRUNN CARSTEN
Chief Executive Officer
2026-01-02
143,200 shares
MALIK KEMAL
Director
2026-01-02
2,600 shares
DAVIS BLAINE
Chief Financial Officer
2026-01-02
37,000 shares
SINGER MICHAEL S.
Director
2026-01-02
2,600 shares
KALAYOGLU MURAT
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-02
2,600 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
RNAC filed its annual 10-K report on March 9, 2026, which includes detailed sections on its business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk disclosures are contained within the full filing, though no detailed excerpts were provided for analysis.
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
Wedbush
2026-03-10
Outperform
Outperform
Cantor Fitzgerald
2026-03-09
Neutral
Overweight
Needham
2026-03-09
Buy
Buy
Needham
2026-01-09
Buy
Buy
HC Wainwright & Co.
2025-11-19
Buy
Buy
BTIG
2025-11-14
Buy
Buy
Past News Coverage
Recent headlines mentioning RNAC from our newsroom.
Newest → oldest
No matching news yet.